As expected, Reckitt Benckiser had agreed to buy Mead Johnson for $90 per share in an all cash transaction. As there is little regulatory worries about the deal, Reckitt Benckiser expects the deal to be completed in Q3 2017. Some investors may be disappointed that a bidding war did not materialise. Mead Johnson’s share rose 5% to $87 in early trades.
— MergerPie (@mergerpie) February 10, 2017